Narcolepsy-China
显著缓解过度嗜睡，创新疗法已递交新药申请 2020-08-28
编者荐语：
以下文章来源于药明康德 ，作者药明康德
全球领先的制药、生物技术以及医疗器械研发开放式能力和技术平台，帮助任何人、任何公司更快、更好地研发新医药产品，探索无限可能
参考资料：
[1] Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy，Retrieved January 22, 2020, from https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-submits-new-drug-application-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy-300991187.html
[2] Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019, Retrieved January 22, 2020, from https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-positive-jzp-258-phase-3-study-data-at-world-sleep-2019-300925650.html
[3] Jazz’s Xyrem follow-up flies through phase 3, poised for 2020 launch, Retrieved January 22, 2020, from fromhttps://www.fiercebiotech.com/biotech/jazz-s-xyrem-follow-up-flies-through-phase-3-poised-for-2020-launch
注：本文旨在介绍医药健康研究进展，不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。
您好！请登录